Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 28, 2015 3:55 PM ET


Company Overview of Advaxis, Inc.

Company Overview

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also develop...

305 College Road East

Princeton, NJ 08540

United States

Founded in 2002

20 Employees





Key Executives for Advaxis, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Age: 46
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Age: 55
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.

Advaxis, Inc. Key Developments

Advaxis, Inc. Announces Licensing Agreement with Knight Therapeutics Inc

Advaxis, Inc. announced that the company has entered into a licensing agreement with Knight Therapeutics Inc. to commercialize in Canada Advaxis's product portfolio including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus (HPV)-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. Under the terms of the licensing agreement, Knight will be responsible for all commercial activities related to Advaxis current and future products, including axalimogene filolisbac, ADXS-PSA and ADXS-HER2, in Canada. Advaxis is eligible to receive double digit royalty as well as sales milestones.

Advaxis, Inc and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac in Combination With Durvalumab

Advaxis, Inc. announced that enrollment has commenced in a phase I/II clinical trial of axalimogene filolisbac (ADXS-HPV), Advaxis's investigational Lm Technology™ immunotherapy, in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), for the treatment of patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The two-part, open-label Phase I/II study is designed to evaluate the safety and efficacy of axalimogene filolisbac as a monotherapy and in combination with durvalumab in approximately 66 patients. Phase I is a dose-confirmation combination study with axalimogene filolisbac and durvalumab, which is expected to establish the maximum tolerated dose. The Phase II portion of the study will randomize patients to receive axalimogene filolisbac monotherapy, durvalumab monotherapy, or the combination.

Advaxis, Inc. Appoints Tom Ridge to the Board of Directors

Advaxis, Inc. appointed Tom Ridge to the company's Board of Directors. Gov. Ridge currently serves as Chief Executive Officer of Ridge Global, offering clients comprehensive risk evaluation to decrease security risks, with a specific emphasis on helping organizations become cyber resilient.

Similar Private Companies By Industry

Company Name Region
PharmaIN Corporation United States
Indi Molecular, Inc. United States
LiRIS Biomedical, Inc. United States
RMH Sciences, LLC United States
GenMetrics United States

Recent Private Companies Transactions

Private Placement
August 26, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Advaxis, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at